2 weeks Ago By Defense World Staff
Northwestern Mutual Wealth Management Co. lifted its stake in shares of Thermo Fisher Scientific Inc. ( NYSE:TMO – Free Report ) by 3.
7% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 111,706 shares of the medical research company’s stock after acquiring an additional 4,030 shares during the quarter. Northwestern Mutual Wealth Management Co.
’s holdings in Thermo Fisher Scientific were worth $61,776,000 at the end of the most recent reporting period. Other hedge funds have also made changes to their positions in the company. Beaumont Financial Advisors LLC boosted its holdings in Thermo Fisher Scientific by 0.
8% during the first quarter. Beaumont Financial Advisors LLC now owns 2,199 shares of the medical research company’s stock worth $1,278,000 after buying an additional 17 shares in the last quarter. Cedar Wealth Management LLC boosted its holdings in Thermo Fisher Scientific by 14.
5% during the first quarter. Cedar Wealth Management LLC now owns 134 shares of the medical research company’s stock worth $78,000 after buying an additional 17 shares in the last quarter. Lafayette Investments Inc.
boosted its stake in Thermo Fisher Scientific by 2.1% in the 2nd quarter. Lafayette Investments Inc.
now owns 830 shares of the medical research company’s stock worth $459,000 after purchasing an additional 17 shares during the period. Patrick M Sweeney & Associates Inc. boosted its stake in Thermo Fisher Scientific by 1.
8% in the 2nd quarter. Patrick M Sweeney & Associates Inc. now owns 1,031 shares of the medical research company’s stock worth $570,000 after purchasing an additional 18 shares during the period.
Finally, Drive Wealth Management LLC boosted its stake in Thermo Fisher Scientific by 0.9% in the 2nd quarter. Drive Wealth Management LLC now owns 2,123 shares of the medical research company’s stock worth $1,175,000 after purchasing an additional 18 shares during the period.
Institutional investors and hedge funds own 89.23% of the company’s stock. Thermo Fisher Scientific Trading Down 0.
8 % Shares of NYSE TMO opened at $614.42 on Monday. Thermo Fisher Scientific Inc.
has a 1-year low of $415.60 and a 1-year high of $627.88.
The company has a market cap of $234.53 billion, a PE ratio of 39.41, a P/E/G ratio of 3.
88 and a beta of 0.78. The company has a current ratio of 1.
72, a quick ratio of 1.37 and a debt-to-equity ratio of 0.64.
The company has a 50-day moving average of $606.08 and a two-hundred day moving average of $581.88.
Thermo Fisher Scientific Announces Dividend The company also recently announced a quarterly dividend, which will be paid on Tuesday, October 15th. Shareholders of record on Friday, September 13th will be issued a $0.39 dividend.
The ex-dividend date of this dividend is Friday, September 13th. This represents a $1.56 annualized dividend and a yield of 0.
25%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is presently 10.01%.
Insiders Place Their Bets In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 10,000 shares of the stock in a transaction on Wednesday, July 31st. The shares were sold at an average price of $617.
21, for a total value of $6,172,100.00. Following the sale, the chief executive officer now directly owns 123,816 shares in the company, valued at $76,420,473.
36. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website . In other Thermo Fisher Scientific news, CEO Marc N.
Casper sold 10,000 shares of the stock in a transaction on Wednesday, July 31st. The shares were sold at an average price of $617.21, for a total value of $6,172,100.
00. Following the sale, the chief executive officer now directly owns 123,816 shares in the company, valued at $76,420,473.36.
The transaction was disclosed in a document filed with the SEC, which is available at the SEC website . Also, CAO Joseph R. Holmes sold 860 shares of the stock in a transaction on Friday, July 26th.
The stock was sold at an average price of $611.03, for a total transaction of $525,485.80.
Following the completion of the sale, the chief accounting officer now owns 1,814 shares in the company, valued at $1,108,408.42. The disclosure for this sale can be found here .
Over the last three months, insiders have sold 23,084 shares of company stock worth $14,094,292. Company insiders own 0.34% of the company’s stock.
Analyst Upgrades and Downgrades A number of equities analysts recently commented on TMO shares. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $767.00 price objective on shares of Thermo Fisher Scientific in a research note on Friday, September 20th.
Barclays decreased their target price on shares of Thermo Fisher Scientific from $615.00 to $600.00 and set an “equal weight” rating for the company in a research note on Friday, June 28th.
Bank of America lifted their target price on shares of Thermo Fisher Scientific from $600.00 to $675.00 and gave the company a “buy” rating in a research note on Monday, September 16th.
Stifel Nicolaus lifted their target price on shares of Thermo Fisher Scientific from $615.00 to $680.00 and gave the company a “buy” rating in a research note on Friday, September 20th.
Finally, Evercore ISI cut their price target on shares of Thermo Fisher Scientific from $615.00 to $600.00 and set an “outperform” rating on the stock in a report on Tuesday, July 2nd.
Four analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $650.41.
Check Out Our Latest Stock Report on TMO Thermo Fisher Scientific Profile ( Free Report ) Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Further Reading Five stocks we like better than Thermo Fisher Scientific Stock Market Sectors: What Are They and How Many Are There? Simon Property REIT: A Safe Bet for Growth and Steady Dividends How to buy stock: A step-by-step guide for beginners CarMax’s Impressive Rally: What Investors Should Watch Next Manufacturing Stocks Investing MarketBeat Week in Review – 9/23 – 9/27 Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.
com's FREE daily email newsletter ..
